Abstract
Background and Purpose— Although intra-arterial (IA) fibrinolysis for acute ischemic stroke has been clinically available for many years, it is not a therapy approved by the US Food and Drug Administration. Single, randomized, clinical trials (RCTs) have suggested beneficial effects, but no single RCT has demonstrated that IA fibrinolysis yields increases in both good (modified Rankin Scale score 0 to 2) and excellent (modified Rankin Scale score 0 to 1) outcomes when compared with the control group. Relatively few participants and inadequate statistical power in single RCTs may have contributed to this difficulty. Method— We performed a systematic literature search to identified RCTs of IA fibrinolysis in acute ischemic stroke. Multiple outcomes were analyzed, with emphasis on good and excellent outcomes at 90 days or at trial end point. Results— The systematic search identified 5 RCTs with 395 participants comparing IA fibrinolysis and control. IA fibrinolysis was associated with increased good (odds ratio=2.05; 95% CI, 1.33 to 3.14; P =0.001) and excellent (odds ratio=2.14; 95% CI, 1.31 to 3.51; P =0.003) outcomes. For additional end points, IA fibrinolysis was associated with increased frequencies of minimal neurologic deficit (National Institutes of Health Stroke Scale score 0 to 1), minimal impairment of activities of daily living (Barthel Index 90 to 100 or 95 to 100), and recanalization. IA fibrinolysis was associated with increased radiological and symptomatic intracerebral hemorrhage. However, there was no difference in mortality between groups. Conclusions— Formal meta-analysis suggests that IA fibrinolysis substantially increases recanalization rates and good and excellent clinical outcomes in acute ischemic stroke. Increased hemorrhage frequencies are not associated with any increase in mortality.
Keywords
MedicineFibrinolysisStroke (engine)Ischemic strokeCardiologyThrombolysisFibrinolytic agentInternal medicineIschemiaTissue plasminogen activatorMyocardial infarction
Affiliated Institutions
Related Publications
PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke
Background and Purpose —To test the safety and recanalization efficacy of intra-arterial local delivery of plasminogen activators in acute ischemic stroke, a randomized trial of...
Revascularization End Points in Stroke Interventional Trials
Background and Purpose— The acute stroke literature lacks a standard convention regarding the critical end point of revascularization. Two distinct parameters may be clinically ...
Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke
Background and Purpose— The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of int...
A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Endovascular Thrombectomy Compared with Best Medical Treatment for Acute Ischemic Stroke
Background Acute ischemic strokes involving occlusion of large vessels usually recanalize poorly following treatment with intravenous thrombolysis. Recent studies have shown hig...
The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)
Background and Purpose —The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous r...
Publication Info
- Year
- 2010
- Type
- review
- Volume
- 41
- Issue
- 5
- Pages
- 932-937
- Citations
- 154
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
154
OpenAlex
Cite This
Meng Lee,
Keun‐Sik Hong,
Jeffrey L. Saver
(2010).
Efficacy of Intra-Arterial Fibrinolysis for Acute Ischemic Stroke.
Stroke
, 41
(5)
, 932-937.
https://doi.org/10.1161/strokeaha.109.574335
Identifiers
- DOI
- 10.1161/strokeaha.109.574335